Experimental drug curaxin joins immunotherapy fight against melanoma
NCT ID NCT05498792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding an experimental drug called CBL0137 (Curaxin) to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma that has spread. Only 12 participants will be enrolled, and the main goal is to check for side effects and find the best dose. The study is still recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CBL0137 (Curaxin) combined with ipilimumab and nivolumab
- What this could lead to
- If it works, this could point toward a more effective combination therapy for advanced melanoma that is harder for the cancer to resist.
- What could go wrong
- This is a very early, tiny study (12 people) focused on safety, not effectiveness. The added drug may cause more side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States